23 October 2025
Latham & Watkins Advises Chugai Pharmaceutical in US$1.085 Billion License Agreement With Rani Therapeutics
Advising firms
Deal team
8 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Chris Hazuka Lead | Latham & Watkins LLP | Partner | corporate | San Diego/Bay Area |
| Darryl Steensma | Latham & Watkins LLP | Counsel | corporate | San Diego |
| Mizuna Sekine | Latham & Watkins LLP | Associate | corporate | Not stated |
| Patrick Chew | Latham & Watkins LLP | Associate | corporate | Not stated |
| Ted Dillman | Latham & Watkins LLP | Partner | finance | Los Angeles |
| Kathleen Wells | Latham & Watkins LLP | Partner | securities | Bay Area |
| Kirt Switzer | Latham & Watkins LLP | Partner | tax | Bay Area |
| Derek Gumm | Latham & Watkins LLP | Associate | tax | Not stated |
5 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 1.08bn (US$1.085 Billion)
- What the figure measures
- Total transaction value
- Client
- Chugai Pharmaceutical Co., Ltd.Buy-side
- Counterparties
- Rani Therapeutics, LLC (Sell-side)